What is causing the mortality in treating the anemia of chronic kidney disease: Erythropoietin dose or hemoglobin level?

Current Opinion in Nephrology and Hypertension

Volumn 19, Issue 5, 2010, Pages 420-424

  Singh, Ajay K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

anemia; chronic kidney disease; erythropoiesis stimulating agent

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CHRONIC KIDNEY DISEASE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MORTALITY; PRIORITY JOURNAL; REVIEW;

ANEMIA; CHRONIC DISEASE; ERYTHROPOIESIS; ERYTHROPOIETIN; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77955921322     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32833cf1d6     Document Type: Review

References (34)

1. Singh AK, Szczech L, Tang KL, et al., CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355:2085-2098.
2. Pfeffer MA, Burdmann EA, Chen CY, et al., TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361:201 9-2032.
3. Wright RJ, Kanagasundaram NS, Quinton R. Darbepoetin alfa and chronic kidney disease. N Engl J Med 2010; 362:653; author reply 655
4. Does TREAT give the boot to ESAs in the treatment of CKD anemia? J Am Soc Nephrol 2010; 21:2-6.
5. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339:584-590.
6. DruekeTB, Locatelli F, Clyne N, etal., CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355:2071-2084.
7. Singh AK. Debate: PRO Position. Should hemoglobin targets for anemic patients with chronic kidney disease be changed? Am J Nephrol 2010; 31:552-556.
8. Cotter DJ, Stefanik K, Zhang Y, et al. Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients. J Clin Epidemiol 2004; 57:1086-1095.
9. Fishbane S, Besarab A. Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. Clin J Am Soc Nephrol 2007; 2:1274-1282.
10. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999; 10:610-619.
11. Regidor DL, Kopple JD, Kovesdy CP, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006; 17:1181-1191.
12. XiaH, Ebben J, MaJZ, Collins AJ. Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 1999; 10:1309-1316.
13. Collins AJ, Li S, St Peter W, et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 2001; 12:2465-2473.
14. Fishbane S, Nissenson AR. The new FDA label for erythropoietin treatment: how does it affect hemoglobin target? Kidney Int 2007; 72:806-813.
15. Valeri CR, Cassidy G, Pivacek LE, et al. Anemia-induced increase in the bleeding time: implications for treatment of nonsurgical blood loss. Transfusion 2001; 41:977-983.
16. Kwaan HC, Wang J. Hyperviscosity in polycythemia vera and other red cell abnormalities. Semin Thromb Hemost 2003; 29:451-458.
17. Stohlawetz PJ, Dzirlo L, Hergovich N, et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 2000; 95:2983-2989.
18. Kirkeby A, Torup L, Bochsen L, et al. High-dose erythropoietin alters platelet reactivity and bleeding time in rodents in contrast to the neuroprotective variant carbamyl-erythropoietin (CEPO). Thromb Haemost 2008; 99:720-728.
19. Patel TV, Mittal BV, Keithi-Reddy SR, et al. Endothelial activation markers in anemic nondialysis chronic kidney disease patients. Nephron Clin Pract 2008; 110:c244-c250.
20. Coleman TR, Westenfelder C, Togel FE, et al. Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoa-gulant and vasoactive activities. Proc Natl Acad Sci USA 2006; 103:5965-5970.
21. Vaziri ND. Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis 1999; 33:821-828.
22. Conlon PJ, Kovalik E, Schumm D, et al. Normalization of hematocrit in hemodialysis patients with cardiac disease does not increase blood pressure. Ren Fail 2000; 22:435-444.
23. Singh A, Patel T, Hertel J, et al. Safety of ferumoxytol in patients with anemia and CKD. Am J Kidney Dis 2008; 52:907-915.
24. Feldman HI, Joffe M, Robinson B, et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 2004; 15:1623-1632.
25. Arcasoy MO. The nonhaematopoietic biological effects of erythropoietin. Br J Haematol 2008; 141:14-31.
26. Brines M. The therapeutic potential of erythropoiesis-stimulating agents for tissue protection: a tale of two receptors. Blood Purif 2010; 29:86-92.
27. Szczech LA, Barnhart HX, Inrig JK, etal. Secondary analysis of the CHOIRtrial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 2008; 74:791-798.
28. Brookhart MA, Schneeweiss S, Avorn J, et al. Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA 2010; 303:857-864.
29. Zhang Y, Thamer M, Stefanik K, etal. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 2004; 44:866-876.
30. Streja E, Kovesdy CP, Greenland S, et al. Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis 2008; 52:727-736.
31. Servilla KS, Singh AK, Hunt WC, et al. Anemia management and association of race with mortality and hospitalization in a large not-for-profit dialysis organization. Am J Kidney Dis 2009; 54:498-510.
32. Bradbury BD, Danese MD, Gleeson M, Critchlow CW. Effect of epoetin alfa dose changes on hemoglobin and mortality in hemodialysis patients with hemoglobin levels persistently below 11 g/dl. Clin J Am Soc Nephrol 2009; 4:630-637.
33. Zhang Y, Thamer M, Cotter D, et al. Estimated effect of epoetin dosage on survival among elderly hemodialysis patients in the United States. Clin J Am Soc Nephrol 2009; 4:638-644.
34. Wang O, Kilpatrick RD, Critchlow CW, et al. Relationship between epoetin alfa dose and mortality: findings from a marginal structural model. Clin J Am Soc Nephrol 2010; 5:182-188.